Nuclear pCHK1 as a potential biomarker of increased sensitivity to ATR inhibition.
Vignesh SundararajanTuan-Zea TanDiana LimYanfen PengAntje Margret WengnerNatalie Yan Li NgoiAnand D JeyasekharanDavid Shao Peng TanPublished in: The Journal of pathology (2022)
Excessive genomic instability coupled with abnormalities in DNA repair pathways induce high levels of "replication stress" when cancer cells propagate. Rather than hampering cancer cell proliferation, novel treatment strategies are turning their attention toward targeting cell cycle checkpoint kinases (such as ATR, CHK1, WEE1 and others) along the DNA damage response and replicative stress response pathways, thereby allowing unrepaired DNA damage to be carried forward towards mitotic catastrophe and apoptosis. The selective inhibitor of ATR kinase elimusertib (BAY 1895344), has demonstrated preclinical and clinical monotherapy activity; however, reliable predictive biomarkers of treatment benefit are still lacking. In this study, using gene expression profiling of 24 cell lines from different cancer types and in a panel of ovarian cancer cell lines, we found that nuclear-specific enrichment of checkpoint kinase 1 (CHK1) correlated with increased sensitivity to elimusertib. Using an advanced multispectral imaging system in subsequent cell line-derived xenograft specimens, we showed a trend between nuclear phosphorylated-CHK1 (pCHK1) staining and increased sensitivity to the ATR inhibitor elimusertib, indicating the potential value of pCHK1 expression as a predictive biomarker of ATR inhibitor sensitivity. This article is protected by copyright. All rights reserved.
Keyphrases
- dna damage response
- dna repair
- cell cycle
- dna damage
- cell proliferation
- oxidative stress
- papillary thyroid
- squamous cell
- genome wide
- copy number
- poor prognosis
- tyrosine kinase
- high resolution
- randomized controlled trial
- cell death
- fluorescence imaging
- combination therapy
- dna methylation
- squamous cell carcinoma
- mass spectrometry
- study protocol
- working memory
- lymph node metastasis
- human health
- clinical trial
- binding protein
- open label
- pi k akt
- drug delivery
- transcription factor
- physical activity
- cancer therapy